Royal Bank of Canada
TXG icon

Royal Bank of Canada’s 10x Genomics TXG Stock Holding History

Royal Bank of Canada’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.12M Buy
133,559
+25,367
+23% +$665K ﹤0.01% 2587
2026
Q1 		$2.3M Buy
108,192
+80
+0.1% +$1.6K ﹤0.01% 2985
2025
Q4 		$1.76M Sell
108,112
-1,321,614
-92% -$20M ﹤0.01% 3219
2025
Q3 		$16.7M Buy
1,429,726
+1,223,602
+594% +$16M ﹤0.01% 1788
2025
Q2 		$2.39M Buy
206,124
+23,288
+13% +$212K ﹤0.01% 3152
2025
Q1 		$1.6M Buy
182,836
+162,665
+806% +$2.05M ﹤0.01% 3112
2024
Q4 		$288K Buy
20,171
+2,189
+12% +$34.5K ﹤0.01% 4516
2024
Q3 		$406K Buy
17,982
+3,399
+23% +$70.3K ﹤0.01% 4265
2024
Q2 		$284K Sell
14,583
-11,519
-44% -$302K ﹤0.01% 4469
2024
Q1 		$979K Buy
26,102
+2,325
+10% +$102K ﹤0.01% 3482
2023
Q4 		$1.33M Buy
23,777
+11,135
+88% +$485K ﹤0.01% 3428
2023
Q3 		$522K Buy
12,642
+1,594
+14% +$82.9K ﹤0.01% 4001
2023
Q2 		$616K Sell
11,048
-1,680
-13% -$90.9K ﹤0.01% 3783
2023
Q1 		$709K Sell
12,728
-13,142
-51% -$614K ﹤0.01% 3607
2022
Q4 		$943K Sell
25,870
-7,737
-23% -$253K ﹤0.01% 3547
2022
Q3 		$956K Sell
33,607
-18,050
-35% -$688K ﹤0.01% 3497
2022
Q2 		$2.34M Buy
51,657
+4,708
+10% +$244K ﹤0.01% 2749
2022
Q1 		$3.57M Sell
46,949
-2,346
-5% -$205K ﹤0.01% 2542
2021
Q4 		$7.34M Buy
49,295
+17,341
+54% +$2.66M ﹤0.01% 2110
2021
Q3 		$4.65M Buy
31,954
+1,019
+3% +$175K ﹤0.01% 2351
2021
Q2 		$6.06M Buy
30,935
+795
+3% +$144K ﹤0.01% 2189
2021
Q1 		$5.46M Buy
30,140
+11,850
+65% +$2.05M ﹤0.01% 2180
2020
Q4 		$2.59M Buy
18,290
+10,384
+131% +$1.51M ﹤0.01% 2687
2020
Q3 		$986K Buy
7,906
+5,954
+305% +$625K ﹤0.01% 3274
2020
Q2 		$175K Buy
1,952
+702
+56% +$54.7K ﹤0.01% 4536
2020
Q1 		$78K Sell
1,250
-2,459
-66% -$192K ﹤0.01% 4923
2019
Q4 		$283K Buy
3,709
+3,626
+4,369% +$218K ﹤0.01% 4388
2019
Q3 		$4K Buy
+83
New +$4.59K ﹤0.01% 6120

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada's TXG Position: Q2 2026 in Review

Royal Bank of Canada increased its 10x Genomics (TXG) stake by 23% in Q2 2026, buying an estimated $665K and bringing the position to 133,559 shares worth $5.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2587.

Royal Bank of Canada first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $16.7M in Q3 2025. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Royal Bank of Canada held 133,559 shares of 10x Genomics worth $5.12M as of Q2 2026.
  • Royal Bank of Canada bought 25,367 10x Genomics shares in Q2 2026, an estimated $665K.
  • 10x Genomics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #2587 holding.
  • Royal Bank of Canada first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • Royal Bank of Canada's 10x Genomics position peaked at $16.7M in Q3 2025.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.